New anesthesia method could cut opioid use after breast reconstruction

NCT ID NCT05439005

Recruiting now Symptom relief Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares opioid-free anesthesia using dexmedetomidine and lidocaine to standard opioid-based anesthesia in 158 women undergoing breast reconstruction after cancer. The goal is to see if the opioid-free approach reduces morphine use and side effects in the first 48 hours after surgery. Researchers will also monitor pain, nausea, and recovery quality.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dexmedetomidine and Lidocaine
What this could lead to: If successful, this could offer a safer anesthesia option for breast reconstruction, reducing opioid use and related side effects like nausea and drowsiness.
What could go wrong: This is a moderate-sized phase 3 trial, but results may not apply to all patients or surgeries. The opioid-free approach might not control pain as effectively for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Gustave Roussy, Cancer Campus, Grand Paris
RECRUITING

Villejuif, France
Institut Curie Paris
RECRUITING

Paris, 75005, France
Institut Curie Saint-Cloud
RECRUITING

Saint-Cloud, 92210, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.